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Abstract: 
The development of new chemical entities against the major diseases caused by parasites is highly 
desired. A library of thirty diamines analogs following a minimalist approach and supported by 
chemoinformatics tools have been prepared and evaluated against apicomplexan parasites. Different 
member of the series of N,N´-disubstituted aliphatic diamines shown in vitro activities at 
submicromolar concentrations and high levels of selectivity against Toxoplasma gondii and in 
chloroquine-sensitive and resistant-strains of Plasmodium falciparum. In order to demonstrate the 
importance of the secondary amines, ten N,N,N',N'-tetrasubstituted aliphatic diamines derivatives were 
synthesized being considerably less active than their disubstituted counterpart. Theoretical studies 
were performed to establish the electronic factors that govern the activity of the compounds. 
Keywords: N,N´-disubstituted Diamines, Polyamines, Anti-apicomplexa, NTDs, Cheminformatics. 
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1. Introduction 
The phylum Apicomplexa includes intracellular protozoan pathogens responsible for many diseases 
with huge global significance in the medical and veterinary field. Plasmodium spp is an apicomplexa 
parasitic alveolate and is the cause of malaria in different parts of the world. Malaria afflicts millions 
of individuals in the tropical zones, causing serious morbidity and mortality. Toxoplasma gondii is the 
etiological agent of toxoplasmosis. This opportunistic pathogen has worldwide distribution, may cause 
cerebral pathology in immunocompromised individuals, and can produce several congenital anomalies 
including induction of miscarriage and neurological disorders.1,2 T. gondii is one of the leading causes 
of focal central nervous system (CNS) disease in AIDS patients. Other apicomplexan organisms such 
as Cryptosporidium parvum and Cyclospora spp. also cause opportunistic infections in humans and 
have relevance in developing countries by causing diarrhoea outbreaks.3,4  
Other members of this phylum including Theileria, Sarcocystis and Babesia spp. are important 
pathogens of animals. The limited arsenal of drugs available against these organisms is insufficient due 
to the rapid emergence of resistance, as is the case for Plasmodium or incomplete activity, as the case 
for chronic Toxoplasmosis. Thus, there is a continuous need develop new chemotherapies in order to 
combat these diseases in a unique mode of action.5,6  
Significant efforts have been undertaken in the last decades to eradicate malaria.7 Between 2000 and 
2015 there was a registered reduction in malaria total estimated cases of more than 14% in 43 out of 
the 99 countries with transmission. Due to the development of resistance, antimalarial drugs which 
have been used to date since the advent of chloroquine, have lost effectiveness around the World.8 
Currently, artemisinin-based combination therapy (ACT) is the mainstay of malaria treatment. 
Unfortunately, there are an increasing number of countries (mostly in East Asia) in which resistance to 
artemisinin has been reported.9,10 Additionally, there is an alarming emergence of multiresistant strains 
in distinct parts of the globe. Furthermore, the resistance in the mosquito vector to pyrethroids has also 
been reported.11 This scenario has led governmental and non-governmental organizations to focus their 
efforts to finding new compounds that serve to combat the disease.12 
Polyamines are essential metabolites that are implicated in many physiological functions including 
DNA replication and repair, being essential for normal cell growth and viability.14 The apparent 
universal distribution of polyamines, and the complexity of compensatory mechanisms that are 
involved to maintain polyamine homeostasis, suggest that these molecules are critical for cell survival. 
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The biosynthesis of polyamines typically starts with the conversion of arginine to putrescine which 
occurs through one of two distinct pathways: arginase coupled with ornithine decarboxylase (ODC), or 
arginine decarboxylase (ADC) coupled with agmatine iminohydrolase. Putrescine can be further 
converted into spermidine and spermine by spermidine and spermine synthases, respectively. When 
polyamines are available, spermine or spermidine can be retro-converted into spermidine and 
putrescine by the consecutive action of spermine/spermidine N1-acetyltransferase (SSAT) and 
polyamine oxidase (PAO).15-17 
The phylum Apicomplexa has a polyamine metabolism that involves a combination of several 
sensitive feedback systems regulating their synthesis, degradation, and transport.18,19 Regulation of 
polyamine biosynthesis is complex and the key biosynthetic enzyme, ODC is one of the most highly 
regulated enzymes. It is present in P. falciparum, but extracts of T. gondii had no detectable ODC and 
ADC activity. Thus, T. gondii lacks a forward-directed polyamine biosynthetic pathway and elucidate 
the need to discover an alternate mechanism to tackle the pathogenicity of this organism.19  
Previously reported studies from Bitonti et al shown a series that bis-(benzyl)-polyamines analogs 
with antimalarial activity against both, a chloroquine-sensitive and -resistant strains of P. falciparum.20 
A selected analog of the series, MDL-27695, (Figure 1) was markedly active and presented a 
synergistic effect with D,L-alpha-difluoromethylornithine (DFMO), being able to cure P. berghei 
infected mice. Initially, MDL-27695 was proposed to target the polyamines biosynthesis. 
Nevertheless, the mechanism of action of these compounds looks likely to be more complex. On one 
hand, Bitonti et al observed that DNA/RNA synthesis was depleted faster with MDL-27695 than upon 
DFMO treatment, on the other polyamines biosynthesis was possibly repressed but might not be the 
only cause of the cytotoxic event.21  
 
[FIGURE 1] 
 
In previous work, we have synthesized N,N’-disubstituted aliphatic diamines and determined their 
activity against parasites of the kinestoplastida group.22 Many analogs were active against T. cruzi, T. 
brucei and L. donovani showing low cytotoxicity. Here, we wanted to expand the analysis of the initial 
collection to determine activity against Toxoplasma and Plasmodium, looking to link the activity with 
the pathophysiological differences between these two parasites. Moreover, we intended to understand 
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their mechanism of action linking their phenotypical differences with their metabolic differences. 
Finally, we were eager to determine the relationship between the physicochemical properties and 
activity of the relevant compounds.  
 
2. Results and discussion  
2.1. Chemistry 
The molecular scaffold of our library was based on the assumption that MDL-27695 interacts with a 
molecular target anchored by two nitrogens requiring a bulky hydrophobic substituent in both terminal 
nitrogens (Figure 1). Following that hypothesis, a minimal version of that scaffold should be a bis- 
substituted benzyl N,N´-disubstituted diamine. That analog should fulfil the steric and polar 
requirements and at the same time be considerably simpler. The library has two sources of diversity: 1) 
the carbon size chain, which brings flexibility and more grades of freedom and 2) the substituent on 
the aromatic ring. The library was prepared in a single step by a double reductive amination between 
the diamines and the benzaldehydes using the procedure by Abdel-Magid et al 23 with minimal 
modifications (Scheme 1). The library was built with all the possible combinations of commercial 
aliphatic diamines with a 3, 4, 6, 8, 10 and 12 carbon chain length and five aromatic aldehydes 
(benzaldehyde, 4-methoxy-benzaldehyde, 4-methoxy benzaldehyde, 3-hydroxy-4-benzyloxy 
benzaldehyde and 3-methoxy-4-benzyloxy benzaldehyde). The library of thirty N,N’ disubstituted 
diamines was prepared in solution, including the dodecyldiamine analogs that were not previously 
reported.22  
The synthesis produced all the desired products with good yield (Table 1, average 77%, ranging 30 
to 99%). The yield was similar across each series (around 80 %). 
 
[SCHEME 1] 
 
2.2. Biological evaluation 
The polyamines pathway in Plasmosdium spp. has been studied during the last 25 years with 
different grades of success. Target-oriented drug design directed to enzymes in the polyamine pathway 
provided promising hits, without showing considerable progress towards becoming lead compounds. 
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Therefore, having in mind all the successful examples via phenotypic screening, and looking to a wide 
spectrum candidate, we decided to assay our collection not only against P. falciparum strains but also 
against T. gondii. Also, cytotoxicity was evaluated in two different cell lines, African green monkey 
kidney epithelial (VERO) cells and human fibroblasts. 
2.2.1. Antiplasmodium activity  
All the analogs were assayed against the chloroquine sensitive Sierra Leona clone (D6) and the 
chloroquine resistant, Indochina clone (W2) strains of P. falciparum. To our satisfaction, most of the 
compounds were active against both the strains. (Table 1). Ninety percent of the collection has an IC50 
below 5 µM, with 73% of the library being more potent than MDL-27695. In general, there are no 
substantial variations in the potency between the sensitive and resistant strain, suggesting that the 
mechanism that confer chloroquine resistance to the W2 strain does not affect sensitivity to this family 
of compounds.  
 
[TABLE 1] 
 
When comparing activities based on the benzyl substituent some clear tendencies emerge. First, 
there is a narrow difference between the more and the less potent member of each series, which ranges 
from 7.61 for R=4-BnO to 1.02 for R=3-MeO,4-BnO (Figure 2).  
 
[FIGURE 2] 
 
These slight differences in antiplasmodium efficacy of the analogs indicate that the diamine chain 
length does not have a strong effect the activity. At the same time, comparing the activity by the same 
diamine linker it seems that it does not considerably affect the potency.  
The analysis of the unsubstituted benzyl derivatives (1 to 6) reveal that compounds with large chains 
(compounds 4, 5 and 6) are very potent (below 1 µM against both strains). A comparison with our 
template compound MDL-27695 reveal that these analogs are 3 to 8 times more active being shorter in 
length and having only two nitrogen atoms. The R=4-MeO series exhibited a similar activity profile, 
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but in this case, compound 11 with a C10 diamine was the most active with IC50 of 0.60 µM. A 
different activity profile was noticed in case of 4-benzyloxy analogs (13 to 18). The tendency changes, 
with 15 was the most active (n=8, IC50=0.39 for D6 and 0.29 µM for W2) and 18 was the least active 
(n=12, IC50=8.00 µM for both D6 and W2 strains). 
Isovanillin analogues 19, 20 and 21 did not show activity up to the maximum concentration tested 
(8.00 µM). That anomaly could be related to the presence of a 3-OH group, which by substantially 
increasing hydrophilicity would alter membrane permeability. Compound 27 was the most active 
analog of the whole library with an IC50 of 260 nM against the P. falciparum D6 strain and SI >31.7, 
only 3-fold less active than chloroquine and artemisinin and 12-fold more active than MDL-27695. 
However, compound 4 showed an IC50 of 370 nM but presents an even higher SI (>39.7). 
As for the resistant strain analogue 5, which is 1.5-fold more active than chloroquine, combines the 
best activity and selectivity, with an IC50 280 nM. Finally, the 3-methoxy-4-benzyloxy benzyl analogs 
are the most active series, with an average of 0.62 µM, with compound 27 (n=6, IC50=0.26 µM) the 
most active and 30 the less active (n=12, IC50=1.28 µM). Interestingly, there is slight difference 
activity among the compounds in this series, suggesting that increasing the chain has minimal effect on 
activity.  
Having completed the analysis of the chain length and the aromatic ring substitution influence on 
the antiplamodial activity, it was important to establish the impact of the nitrogen substitution. There 
are many literature reports of monosubstituted diamines, but surprisingly, no precedents of bioactive 
tetrasubstituted aliphatic diamine analogs as antiparasitic agents.24 With that idea in mind, ten 
tetrasubstituted analogs were prepared. Only the simplest aromatic substituents (R=H and 4-OMe) and 
five diamines (n=3,4,6,8 and 10) were selected, looking to comply with Lipinsky’s rules (MW<500 Da 
and logP<5), additionally dodecylamine analogs were not considered because they were, on average, 
less active. In this opportunity, a different methodology for the synthesis was required. A one-pot 
procedure was selected, where two consecutive reductive aminations occurred using sodium triacetoxy 
borohydride, acetic acid in DCM art room temperature.25,26 Ten new products were prepared (Scheme 
2) with 22% global yield (Table 1). The main drawback of the reaction was the aldehyde reduction that 
forced using at least 4.5 equivalents of that component. Unfortunately, when more equivalents were 
used, the amount of the benzyl alcohol increased, impeding a clean separation of the product by 
column chromatography. 
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[SCHEME 2] 
 
The new analogs were evaluated against the D6 and W2 strains of P. falciparum and did not show 
activity at the maximum concentration tested (8 µM). A more detailed analysis revealed that the most 
active member of each series of the disubstituted analogs were at least 40 times (Compound 4, R=H, 
IC50 P.f. D6 = 0.37 µM) and 19 times (compound 11, R=4-MeO, IC50 P.f. D6 = 0.60 µM) more active 
than the tetrasubstituted analogs 34 and 40 (both P.f. D6 > 8.0 µM), respectively.  
The antimalarial activity of N,N-disubstituted putrescine and trimethylenediamine had been 
previously reported.27 Comparing the activity of the reported N,N-disubstituted with the corresponding 
N,N´-disubstituted analogs has shown that the last ones were always more active (between 1.5 to 7 
times more potent). These results clearly demonstrate that the secondary amine is an important 
structural feature required for the antimalarial activity, being the N,N´-disubstitution the pattern that 
provided the best results. 
2.2.2. Anti-Toxoplasma gondii activity. 
To test activity of our library of diamines against T. gondii we cultured parasites on human foreskin 
fibroblasts in the presence of drug at 1µM or of DMSO as solvent control for 5 days, at which time 
point cells were fixed and stained to monitor parasite growth.  The results, presented in Table 1, show 
that in general the molecules in our library are not as effective in inhibiting T. gondii growth as they 
are with P. falciparum. Compounds 5, 12, 13, 17 and 25 (20 % of the collection) were the most 
effective against T. gondii and exhibited at least 75% of inhibition compared with the untreated 
parasites. Interestingly, compound 5 was also the most active member of the benzyl series against P. 
falciparum (IC50=0.48µM). Compound 12 is the most active on T. gondii of the 4-methoxy benzyl 
series, and is just two carbons larger than the analog of that family with best antiplasmodial activity. 
The 4-benzyloxy benzyl containing compounds 13 and 17, which have 3 and 10 carbon chain 
respectively, show 75 % of T. gondii growth inhibition. Compound 15, which did not affect T. gondii 
growth was the member of that series (4-benzyloxy benzyl) with the best antiplasmodial. The 3-
methoxy-4hydroxy benzyl and the 3-methoxy 4-benzyloxy benzyl series contains a second oxygen on 
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the benzyl ring. For the isovanillin analogues, short chains derivatives (20, 21) were the most active, 
behaving differently on P. falciparum were the longer analogs were the most potent.  
Finally, the IC50 of most active analogs was determined, revealing that compounds 13 and 25 has an 
IC50= 2.97 µM and 25, the most active member of the series has an IC50= 1.53 µM. Interestingly, none 
of these compounds displayed cytotoxicity on fibroblast at 10 µM, providing an SI as anti-T. gondii of 
3.37 and 6.54 for 13 and 25, respectively. In summary, the overall library behavior was different 
between the two parasite species, showing that tachyzoites were not affected in the same way that 
Plasmodium erythrocytic stage (trophozoites) suggesting a different action mechanism in both 
parasites. 
2.2.3. Cytotoxicity. 
Vero cells are an excellent model for test cytotoxicity in vitro because is an aneuploid and a 
continuous cell linage. The library was tested for their effect on Vero cells to a maximum 
concentration of 8 µM. Only five compounds, (9, 13, 14, 25 and 28), which corresponds to 16 % of our 
library, were cytotoxic with a range of IC50 between 4 to 8 µM. These five diamines analogues have a 
short carbon chain length, and all, with the exemption of compound 9, have benzyloxy substituents on 
position 4 of the aromatic ring. Nonetheless, these five compounds, particularly 25 and 28 exhibit 
excellent activities against apicomplexa parasites. Therefore, even being cytotoxic at low micromolar 
they are 10-fold higher as antimalarial providing good SI (15.9 and 14.6, respectively). 
2.3. Cheminformatics and clusters analysis. 
The rationale used to design this targeted library of symmetrical N,N’-disubstituted diamines 
allowed only two entries for scaffold modifications providing a collection that has low chemical 
diversity. However, using the ChemMineTools online platform,28 it was possible to cluster the 
collection based on their structural matrixes. This information was useful to establish a structural-
activity relationship correlating the activity and topological parameters. (Figure 3). The outcome of 
this calculation revealed the precedence of three main clusters (marked in green, red and blue in 
Figure 3) and ten secondary clusters (labelled from A to J in Table 1). 
The main cluster (green) contains the most active analogs in both parasites. This cluster has two sets 
of subclusters: one is represented for compounds 13, 14, 25 and 26 (clusters G and H) and the second 
is represented by 15, 16, 17, 18, 27, 28, 29 and 30 (clusters I and J). When activities are considered, 
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the first subcluster includes analogs with the highest potency towards both parasites. The second 
subcluster is more active against P. falciparum. The percentage of growth inhibition of Toxoplasma is 
low with the exception of compound 17.  
 
[FIGURE 3] 
 
2.3.1. Physicochemical characteristics and ADME-Tox.  
Addressing pharmacokinetic properties at the early stages of drug development reduces the chances 
of failure on clinical trials. To characterize the profile of our analogs, we performed computational 
studies of all compounds to predict their adsorption, distribution, metabolism and excretion (ADME) 
properties, Lipinski's rule of five, toxicity liabilities and drug likeness. The in silico toxicology 
calculated by the OSIRIS property explorer platform29 indicates that none of the products prepared are 
potentially mutagenic, irritant, teratogenic, or toxic for sexual reproduction. The only exception is the 
isovanillin subfamily derivatives, which are potentially mutagenic. Likewise, this subset demonstrated 
to possess the lowest levels of biological activities, therefore they are not good candidates for future 
optimizing steps.   
On the other hand, the most relevant parameters (molecular weight, polar surface area, volume, 
logBB and logP) of the collection allow us to predict the potential of the compounds as leaders, 
possible administration routes and to enrich SAR. To that purpose the Molinspiration30 and 
ChemAxon31 platforms were used to calculate these physicochemical parameters including the 
predominant molecular form at physiological pH (Table 2). 
According to Lipinski's rule of five, a potential drug candidate should be orally active if the 
molecular weight is ≤ 500 Da, logP ≤ 5, the number of hydrogen bond acceptors ≤ 10 and the number 
of hydrogen bond donors ≤5. The analysis of the collection revealed that 66.6 % of the collection has 
MW<500 (256 to 654 Da) and 83.3 % has logP < 5 (-1.14 to 7.79). (Figure 4)  
According to Hammett and Hansch's principle, a relationship between lipophilicity descriptors like 
logP and biological activity most commonly produce a parabolic correlation. In the case of our 
collection, the logP values of the 30 compounds fluctuate between -1.14 and 7.79. A correlation is 
clearly observed for P. falciparum (Figure 4), where most active analogs have logP between 2.47 and 
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4.95. By contrast, the correlation for T. gondii is not clear (Figure 5). However, we could constrain the 
logP range values between 2.66 to 3.75 for the highest values of activity against T. gondii.  
However, our library contains ionizable groups that are charged at physiological pH, which make 
logD a better descriptor of the lipophilicity of these molecules. The calculated logD at physiological 
pH (7.4) of the collection is presented in Table 2, with 90 % of the collection being ≤ 5 (-1.09 to 5.92). 
Given the chemical nature of the amine groups in the designed structures, the lipophilicity decreases 
markedly as the pH drops. This fact would suggest that the molecule could have a better interaction in 
the acidic environment of some organelles, in the same way as ethambutol does within lysosomes and 
autophagosomes.32 In summary, this analysis reveals that most of the compounds has good potential to 
be orally active drug candidates. 
The distribution of the compounds between blood and brain is a very important consideration for 
new candidate drug molecules. In case T. gondii, which effectively infects neurons and causes disease 
in the brain, good drug candidates must be able to cross the blood brain barrier (BBB). To predict that 
properly we calculated the logBB using COSMOquick.33 This calculation shows that 75% of our 
compounds have logBB > 0.3. It has been shown that molecules with logBB > 0.3 cross the BBB 
readily while molecules with logBB < −1 are poorly distributed to the brain,34,35 thus our library 
includes numerous compounds that would be expected to enter the brain. 
 
[FIGURE 4] 
 
[FIGURE 5] 
 
[TABLE 2] 
 
2.4. Analysis of the molecular electrostatic potential of the aromatic portion.  
Molecular electrostatic potentials (MEPs) were used for analyzing drug-receptor and enzyme-
substrate interaction and other recognition processes, based on the assumption that those potentials 
described how different molecular regions will interact with other approaching chemical species. 
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In order to determine how the electronic potential of the aromatic portion of the analogs affects the 
activity, a tridimensional molecular electrostatic potential map of the aromatic portion of the prepared 
N,N´-dibenzyl aliphatic diamines derivatives were performed at the van der Waals contact surface. To 
simplify the calculations, only substituted N-methyl benzyl were used (Figure 6a. R=H; R=4-OMe; 
R=4-OBn; R=3-OH,4-OMe; R=3-MeO,4-BnO). The geometries of the groups were optimized using 
B3LYP functional along with 6-311++G(d,p). (Figure 6b) The electrostatic potentials, superimposed 
onto a surface of constant electron charge density were calculated (0.001 e/au3, Figure 6c).  
It is well known that electrostatic potential has been defined as the energy of interaction of a 
positively charge point with the nuclei and the electrons of a molecule. On Figure 6C the coloring area 
represents the electrostatic potential, V(r), providing a measurement of the molecular charge 
distribution. The calculated MEP maps for the five analogs that go from –0.1408 au in deepest red for 
the strongest attraction, to +0.1152 au in deepest blue for the strongest repulsion. Negative regions 
V(r) are usually associated with a lone pair of electronegative atoms and the π electrons of the 
unsaturated hydrocarbons. In this case, the MEPs are different for each of the five analogs studied and, 
as expected, is affected by the aromatic ring subtituents. The negative potentials are localized at the 
oxygens of the phenols and methoxy groups. On the other side, the positive potential is localized on 
the nitrogen amine and is significantly affected by the substituent on the aromatic ring.  
When the activity of each series was correlated with the electrotactic potential, two clear tendencies 
emerged. On one side, the activity of the analogs with benzyloxy group seems governed by steric 
effects. On the other side, the activity of the series is clearly associated to the negative electrostatic 
potential, being detrimental to the antiplasmodial activity. 
 
[FIGURE 6] 
 
3. Conclusions 
Enzymes are usually arranged into symmetrical homodimers or tetramers, with the consequent 
active site organization in a highly symmetrical fashion. Thus, symmetrical inhibitors or biological 
actuators will correspond generally to their binding site.36 Numerous examples of symmetrical active 
compounds have been reported including anticancer,37,38 antiparasitic,39,40 antitubercular41 and enzyme 
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inhibitors,42,43 between others. The compounds designed and prepared on this work were inspired on 
the symmetrical compound MDL-27695. We were looking to simplify that compound´s structure, 
removing nitrogens from the carbon chain and inquiring the effect of oxygenated substituents of the 
aromatic ring on the activity. Therefore, we searched for a fast and easy way to explore the chemical 
space of the proposed disubstituted N,N´- aliphatic diamines. A major advantage of the proposed 
scaffold lies in the fact that the synthesis of symmetrical derivatives is extremely straightforward and 
only required commercially available starting materials. The synthesis did not need additional 
protection/deprotection steps, minimizing the synthesis to a single-step, being a clear example of atom 
economy and green chemistry.44,45 
It has been suggested that symmetry and planarity disruption is a valuable strategy to improve 
aqueous solubility.46 The synthesized compounds are very flexible preventing a good packing that 
facilitates the dissolution process. Also, the two nitrogen atoms on the aliphatic chain provide the 
required polarity to improve the water solubility and bioavailability. Therefore, from the solubility 
point of view, the symmetrical scaffold prepared did not represent a disadvantage.  
The one-pot synthetic procedure provided 30 symmetric derivatives in good yields. In vitro studies 
have demonstrated that most of the analogs (26 of 30 compounds) are active against P. falciparum at 
micromolar level or below (9 compounds at submicromolar level). On the other hand, the related 
parasite T. gondii does not seem as sensitive to these type of compounds (6 of 30 compounds shows at 
least 75% of activity at 1 µM). The differences on the sensitivity between T. gondii and P. falciparum 
could be attributed to a favoured incorporation to the red bloods cells or the interaction with different 
molecular targets due to their metabolic divergences. 
A series of tetrasubstituted N,N´-aliphatic diamines were prepared being considerable less active 
against both P. falciparum strains than the bis-substituted counterpart demonstrating the importance of 
the secondary amine on the activity.  
A summary of the structure-activity analysis is detailed on Figure 7. As can be seen, the 
antimalarial activity of the compounds is fairly responsive to the structural variations in most of the 
series, with certain substituents increasing activity, like R=H, or R=3-MeO,4-BnO. MEPs results 
clearly shown that the aromatic subtituents affect the electrostatic potential of the nitrogen and the 
aromatic ring and that, together with the steric factors, can be correlated with the activity. Chain length 
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appears to slightly influence potency, being the electronic and the steric the most critical factors 
modulating the activity. 
The selection of the best drug candidate as antimalarial and anti-T. gondii should combine a low 
IC50 values with Lipinski´s rules compliance, low cytotoxicity (high SI) and ideal range of logBB 
(only for T. gondii). Following that premise, analogs 4, 5, 15, 26 and 27 are the most promising 
antimalarial candidates, having submicromolar IC50 and SI>20. Filtering out the selection by the 
ADME parameters points to compound 4 as the best candidate. In the case of T. gondii, analogs 13 and 
25 based on the activity are the most promising, but of these only 13 is predicted to cross the BBB, 
which would make it the best candidate for future studies (Figure 5). It is likely that the mechanism of 
action of these compounds differs between these two parasites. Additionally, the targets and 
mechanisms of action in each parasite might be different across the different series.  Future studies 
with the best candidates will focus on elucidating mode of action. The fact that similar compounds act 
by different mechanisms in trypanosomatids22,47 and the pathogenic fungus Pneumocystis carinii48 
support this hypothesis. Polyamine oxidase have been studied as a possible target of MDL-27695 on P. 
falciparum.49 The oxidation of that compound by purified rat liver oxidase release benzaldehyde and 
the N-monosubstituted analog, then goes to another oxidation cycle releasing the free polyamine. Also, 
polyamine concentration increases inside P. falciparum infected red blood cells by newly recruited 
transporters. 
Similar degradation products have been studied on Plasmodium falciparum,50 displaying similar 
potency to the bis-benzyl disubstituted analogs but holding a bulky antracene ring. Having in mind that 
monosubstituted diamines have been described as polyamine transport inhibitors,51-53 a possible action 
mechanism could involve oxidation to activate the compound that then inhibit the polyamine transport.  
In conclusion, the structural simplification of MDL-27695 provided potent antimalarial analogs 
validating our initial hypothesis. The fact that compounds 4 and 5, which has strong similarities to 
MDL-27695 but only have 2 nitrogens, supports the idea that the bis-N-benzyl moiety could be acting 
as the pharmacophore within those structures. Lastly, the N,N´-disubstituted aliphatic diamine analogs 
provides  unique tools to develop new antiparasitic agents and to study biological processes related to 
polyamines metabolism. A possible multitarget action mechanism should be validated by non-directed 
metabolomics and proteomics study. 
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[FIGURE 7] 
 
4. Material and Methods 
4.1. General Information 
1H and 13C NMR spectra were acquired on a Bruker Avance II 300 MHz (75.13 MHz) using CDCl3 
as solvent. Chemical shifts (δ) were reported in ppm downfield from tetramethylsilane (TMS) at 0 ppm 
as internal standard and coupling constants (J) are in hertz (Hz). Chemical shifts for carbon nuclear 
magnetic resonance (13C NMR) spectra are reported in parts per million relative to the center line of 
the CDCl3 triplet at 76.9 ppm. The following abbreviations are used to indicate NMR signal 
multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, p = pentet, br = broad 
signal. High-resolution mass spectra (HRMS) were recorded on a Bruker MicroTOF II with lock spray 
source. IR spectra were obtained using an FTIR Shimadzu spectrometer and only partial spectral data 
are listed. Chemical reagents were purchased from commercial suppliers and used without further 
purification, unless otherwise noted. Solvents were analytical grade or were purified by standard 
procedures prior to use. Yields were calculated for material judged homogeneous by thin layer 
chromatography (TLC) and nuclear magnetic resonance (1H-NMR). All reactions were monitored by 
thin layer chromatography performed on silica gel 60 F254 pre-coated aluminium sheets, visualized by 
a 254 nm UV lamp, and stained with an ethanolic solution of 4-anisaldehyde. Column flash 
chromatography was performed using silica gel 60 (230–400 mesh). 
4.2. In vitro activity against P. falciparum (IC50). 
Antimalarial activity was determined in vitro on the chloroquine sensitive (D6, Sierra Leone) and 
resistant (W2, Indo China) strains of P. falciparum. The 96-well microplate assay was based on the 
evaluation of the effect of compounds on the growth of asynchronous cultures of P. falciparum, 
determined by the assay of parasite lactate dehydrogenase (pLDH) activity. The appropriate dilutions 
of the compounds were prepared in DMSO or RPMI-1640 medium and added to the cultures of P. 
falciparum (2% hematocrit, 2% parasitemia) setup in clear flat bottomed 96-well plates. The plates 
were placed into the humidified chamber and flushed with a gas mixture of 90% N2, 5% CO2 and 5% 
O2. The cultures were incubated at 37 °C for 48 h. Growth of the parasite in each well was determined 
by pLDH assay using Malstat reagent. The medium and red blood cells (RBC) controls were also setup 
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in each plate. The standard antimalarial agent chloroquine and artemisinin were used as the positive 
controls. 
4.3 In vitro activity against T. gondii. 
Toxoplasma parasites (RH strain parasites expressing the green fluorescent protein, GFP) were 
maintained in human foreskin fibroblast (HFF) monolayers in Dulbecco’s medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, and 100 g/ml streptomycin. 
Uninfected and infected HFFs cells were maintained in a humidified incubator at 37 °C with 5% CO2. 
For primary screen, 103 parasites were allowed to infect a confluent HFF monolayer. At 8 hours post-
infection, the medium was replaced with medium containing 1 or 10 µM of each compound. Three 
days later cultures were monitored by fluorescence microscopy to monitor parasite growth. To 
determine IC50 HFFs were infected with 80 parasites and after four hours extracellular parasites were 
washed off and media with drug at a range of concentrations was added. At 5 days post-infection, 
cultures were fixed with methanol for 2 minutes and stained with crystal violet to visualized plaques 
which were enumerated. Percentage survival was calculated by dividing the number of plaques in drug 
over that in equivalent amount of DMSO. Experiments were performed in three experimental and 
biological replicates. 
4.4. Cytotoxicity assay on Vero cells. 
The in vitro cytotoxicity was determined against mammalian kidney fibroblasts (VERO). The assay 
was performed in 96-well tissue culture-treated plates as described earlier. Briefly, cells were seeded to 
the wells of the plate (25,000 cells/well) and incubated for 24 h. Samples were added and plates were 
again incubated for 48 h. The number of viable cells was counted and the plot for EC50 performed. 
4.5. ADME/toxicity predictions.  
Computational modeling to estimate the bioavailability, aqueous solubility, blood brain barrier 
potential, human intestinal absorption, mutagenicity, and toxicity for the compounds was performed 
using the ChemMineTools and Osiris Property. 
4.6. General procedure for N,N-diamines disubstituted synthesis  
Aldehyde (3 eq dissolved in the same mixture of solvents) was added to a solution of diamine (1 eq) 
in an anhydrous mixture of DCM:methanol (3:1). The mixture was refluxed overnight, the solvent was 
evaporated and the crude di-imine was dissolved in an anhydrous mixture of DCM:methanol (1:1). 
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The solution was cooled at 0 oC, and sodium borohydride (3 eq) was added portion wise. The reaction 
was allowed to warm to room temperature and stirred for additional 12 hours. Excess of sodium 
borohydride was quenched acidifying with 10% HCl, with subsequent addition of ammonium 
hydroxide to reach a basic pH. Phases were separated and the aqueous phase extracted with DCM (3 x 
20 mL). Combined organic extracts were dried with sodium sulphate and evaporated. Products were 
purified by flash chromatography.  
4.6.1 Synthesis of N1,N3-dibenzylpropane-1,3-diamine (1). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 97 mg of white solid (isolated yield: 79 %). 1H NMR (CDCl3) δ 7.31 
(m, 10H, aromatics); 3.78 (s, 4H, Ar-CH2); 2.72 (t, 4H, J = 6.6 Hz, N-CH2); 1.74 (m, 2H, C2-H). 13C 
NMR (CDCl3) δ 140.3 (C); 128.4 (CH); 128.2 (CH); 126.9 (CH); 54.1 (CH2); 48.0 (CH2); 30.0 (CH2). 
IR υ 3296 (R-NH-R1); 3026 (Ar-H); 1119 (C-N-C); 697 (monosubstituted aromatic) cm-1. ESI-
HRMS: calculated mass for C17H23N2 (M+H+) 255.1861; found 255.1853. 
4.6.2. Synthesis of N1,N4-dibenzylbutane-1,4-diamine (2). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 88 mg of white solid (isolated yield: 73 %). 1H NMR (CDCl3) δ 7.28 
(m, 10H, aromatics); 3.78 (s, 4H, Ar-CH2); 2.64 (t, 4H, J=6.6 Hz, N-CH2); 1.57 (m, 4H, C2-H and C3-
H). 13C NMR (CDCl3) δ 139.6 (C); 128.4 (CH); 128.2 (CH); 127.1 (CH); 53.6 (CH2); 48.9 (CH2); 27.6 
(CH2). IR υ 3311 (R-NH-R1); 1120 (C-N-C); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: 
calculated mass for C18H25N2 (M+H+) 269.2018; found 269.2011. 
4.6.3. Synthesis of N1,N6-dibenzylhexane-1,6-diamine (3). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 47 mg of white solid (isolated yield: 46 %). 1H NMR (CDCl3) δ 7.28 
(m, 10H, aromatics); 3.78 (s, 4H, Ar-CH2); 2.61 (t, 4H, J= 7.2 Hz, N-CH2); 1.49 (m, 4H, C2-H and 
C5-H); 1.34 (m, 4H, C3-H and C4-H). 13C NMR (CDCl3) δ 140.3 (C); 128.4 (CH); 128.2 (CH); 126.9 
(CH); 54.0 (CH2); 49.3 (CH2); 29.9 (CH2); 27.3 (CH2). IR υ 3312 (R-NH-R1); 3026 (Ar-H); 1119 (C-
N-C); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C20H29N2 (M+H+) 
297.2331; found 297.2328. 
4.6.4. Synthesis of N1,N8-dibenzyloctane-1,8-diamine (4). 
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Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 85 mg of white solid (isolated yield: 94 %). 1H NMR (CDCl3) δ 7.30 
(m, 10H, aromatics); 3.82 (s, 4H, Ar-CH2); 2.67 (t, 4H, J= 7.2 Hz, NCH2); 1.52 (m, 4H, C2-H and C7-
H); 1.30 (s, 8H, C3-H to C6-H). 13C NMR (CDCl3) δ 140.2 (C); 128.4 (CH); 128.2 (CH); 126.9 (CH); 
53.9 (CH2); 49.3 (CH2); 29.9 (CH2); 29.5 (CH2); 27.5 (CH2). IR υ 3307 (R-NH-R1); 3026 (Ar-H); 
1121 (C-N-C); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C22H33N2 
(M+H+) 325.2644; found 325.2660. 
4.6.5. Synthesis of N1,N10-dibenzyldecane-1,10-diamine (5). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 73 mg of white solid (isolated yield: 89%). 1H NMR (CDCl3) δ 7.31 
(m, 10H, Ar-H); 3.84 (s, 4H, Ar-CH2); 2.65 (t, 4H, J= 7.20 Hz, N-CH2); 1.55 (m, 4H, C2-H and C9-
H); 1.25 (m, 12H, C3-H to C8-H). 13C NMR (CDCl3) δ 136.7 (C); 128.9 (CH); 128.6 (CH); 127.7 
(CH); 52.4 (CH2); 47.9 (CH2); 29.3 (CH2); 29.2 (CH2); 28.2 (CH2); 27.0 (CH2). IR υ 3307 (R-NH-R1); 
3026 (Ar-H); 1121 (C-N-C); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: calculated mass for 
C24H37N2 (M+H+) 353.2957; found 353.2966. 
4.6.6. Synthesis of N1,N12-dibenzyldodecane-1,12-diamine (6). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 97 mg of white solid (isolated yield: 79 %). 1H NMR (CDCl3) δ 7.31 
(m, 10H, Ar-H); 3.84 (s, 4H, Ar-CH2); 2.65 (t, 4H, J= 7.20 Hz, N-CH2); 1.55 (m, 4H, C2-H and C11-
H); 1.25 (m, 16H, C3-H to C10-H). 13C NMR (CDCl3) δ 136.7 (C); 128.9 (CH); 128.6 (CH); 127.7 
(CH); 52.4 (CH2); 47.9 (CH2); 29.3 (CH2); 29.2 (CH2); 28.2 (CH2); 27.0 (CH2). IR υ 3307 (R-NH-R1); 
3026 (Ar-H); 1121 (C-N-C); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: calculated mass for 
C26H41N2 (M+H+) 381.3255; found 381.3264. 
4.6.7. Synthesis of N1,N3-bis(4-methoxybenzyl)propane-1,3-diamine (7).  
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 132 mg of colourless oil (isolated yield: 78 %). 1H NMR (CDCl3) δ 
7.21 (d, 4H, J= 8.7 Hz, C2’-H); 6.85 (d, 4H, J= 8.7 Hz, C3’-H); 3.79 (s, 6H, O-CH3); 3.71 (s, 4H, Ar-
CH2); 2.68 (t, 4H, J= 6.6 Hz, N-CH2); 1.71 (m, 2H, C2-H). 13C NMR (CDCl3) δ 158.6 (C); 132.7 (C); 
129.3 (CH); 113.7 (CH); 55.2 (CH3); 53.5(CH2); 47.9 (CH2); 30.2 (CH2). IR υ 3301 (R-NH-R1); 3062 
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(Ar-H); 1176 (C-N-C); 1243 and 1036 (Ar-O-C); 818 (disubstituted aromatic) cm-1. ESI-HRMS: 
calculated mass for C19H27N2O2 (M+H+) 315.2073; found 315.2087. 
4.6.8. Synthesis of N1,N4-bis(4-methoxybenzyl)butane-1,4-diamine (8). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 115 mg of white solid (isolated yield: 77 %). 1H NMR (CDCl3) δ 
7.19 (d, 4H, J= 8.7 Hz, C2’-H); 6.83 (d, 4H, J= 8.7 Hz, C3’-H); 3.75 (s, 6H, O-CH3); 3.68 (s, 4H, Ar-
CH2); 2.58 (t, 4H, J= 6.6 Hz, N-CH2); 1.51 (m, 4H, C2-H and C3-H). 13C NMR (CDCl3) δ 158.6 (C); 
132.4 (C); 129.3 (CH); 113.8 (CH); 55.2 (CH3); 53.3 (CH2); 49.1 (CH2); 27.8 (CH2). IR υ 3314(R-NH-
R1); 2997 (Ar-H); 1246 and 1036 (Ar-O-C); 1174 (C-N-C); 818(disubstituted aromatic) cm-1. ESI-
HRMS: calculated mass for C20H29N2O2 (M+H+) 329.229; found 329.2233. 
4.6.9. Synthesis of N1,N6-bis(4-methoxybenzyl)hexane-1,6-diamine (9).  
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 37 mg of white solid (isolated yield: 30 %). 1H NMR (CDCl3) δ 7.23 
(d, 4H, J= 8.7 Hz, C2’-H); 6.86 (d, 4H, J= 8.7 Hz, C3’-H); 3.79 (s, 6H, -CH3); 3.71 (s, 4H, Ar-CH2); 
2.59 (t, 4H, J= 6.9 Hz, N-CH2); 1.48 (m, 4H, C2-H and C5-H); 1.33 (m, 4H, C3-H and C4-H). 13C 
NMR (CDCl3) δ 158.6 (C); 132.5 (C); 129.3 (CH); 113.8 (CH); 55.2 (CH3); 53.4(CH2); 49.2 (CH2); 
29.9 (CH2); 27.3 (CH2). IR υ 3296(R-NH-R1); 2957 (Ar-H); 1252 and 1033 (Ar-O-C); 1103 (C-N-C); 
818 (disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C22H33N2O2 (M+H+) 357.2542; 
found 357.2531. 
4.6.10. Synthesis of N1,N8-bis(4-methoxybenzyl)octane-1,8-diamine (10). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 95 mg of white solid (isolated yield: 59 %). 1H NMR (CDCl3) δ 7.23 
(d, 4H, J= 8.7 Hz, C2’-H); 6.85 (d, 4H, J= 8.7 Hz, C3’-H); 3.78 (s, 6H, O-CH3); 3.71 (s, 4H, Ar-CH2); 
2.59 (t, 4H, J= 6.9 Hz, N-CH2); 1.48 (m, 4H, C2-H and C7-H); 1.28 (m, 8H, C3-H to C6-H). 13C NMR 
(CDCl3) δ 158.6 (C); 132.4 (C); 129.3 (CH); 113.8 (CH); 55.2 (CH3); 53.4 (CH2); 49.3 (CH2); 29.9 
(CH2); 29.5 (CH2); 27.3 (CH2). IR υ 3307 (R-NH-R1); 3026 (Ar-H);1121 (C-N-C); 697 
(monosubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C24H37N2O2 (M+H+) 385.2855; 
found: 385.2857. 
4.6.11. Synthesis of N1,N10-bis(4-methoxybenzyl)decane-1,10-diamine (11). 
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Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 63 mg of white solid (isolated yield: 66 %). 1H NMR (CDCl3) δ 7.26 
(d, 4H, J= 8.7 Hz, C2’-H); 6.86 (d, 4H, J= 8.7 Hz, C3’-H); 3.79 (s, 6H, O-CH3); 3.75 (s, 4H, Ar-CH2); 
2.62 (t, 4H, J= 7.2 Hz, NH-CH2); 1.52 (m, 4H, C2-H and C9-H); 1.26 (m, 12H, C3-H to C8-H). 13C 
NMR (CDCl3) δ 158.9 (C); 130.2 (C); 129.8 (CH); 113.9 (CH); 55.2 (CH3); 52.4 (CH2); 48.9 (CH2); 
29.4 (CH2); 29.3 (CH2); 28.9 (CH2); 27.2 (CH2). IR υ 3392(R-NH-R1); 1253 and 1033 (Ar-O-C); 1177 
(C-N-C); 818 (disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C26H41N2O2 (M+H+) 
413.3168. found 413.3172. 
4.6.12. Synthesis of N1,N12-bis(4-methoxybenzyl)dodecane-1,12-diamine (12). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 109 mg of white solid (isolated yield: 99 %). 1H NMR (CDCl3) δ 
7.26 (d, 4H, J= 8.7 Hz, C2’-H); 6.86 (d, 4H, J= 8.7 Hz, C3’-H); 3.79 (s, 6H, O-CH3); 3.75 (s, 4H, Ar-
CH2); 2.62 (t, 4H, J= 7.2 Hz, N-CH2); 1.52 (m, 4H, C2-H and C11-H); 1.26 (m, 16H, C3-H to C10-
H).13C NMR (CDCl3) δ 158.9 (C); 130.2 (C); 129.8 (CH); 113.9 (CH); 55.2 (CH3); 52.4 (CH2); 48.9 
(CH2); 29.4 (CH2); 29.3 (CH2); 28.9 (CH2); 27.2 (CH2). IR υ 3392(R-NH-R1); 1253 and 1033 (Ar-O-
C); 1177 (C-N-C); 818 (disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C28H45N2O2 
(M+H+) 441.3475; found 441.3462. 
4.6.13. Synthesis of N1,N3-bis(4-(benzyloxy)benzyl)propane-1,3-diamine (13). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 170 mg of white solid (isolated yield: 67 %). 1H NMR (CDCl3) δ7.41 
(m, 10H, aromatics 4’-benzyloxy) 7.21 (d, 4H, J= 8.7 Hz, C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
5.05 (s, 4H, Ar-CH2-O); 3.71 (s, 4H, Ar-CH2-N);2.69 (t, 4H, J= 6.9 Hz, N-CH2); 1.72 (m, 2H, C2). 
13C NMR (CDCl3) δ 157.9 (C); 137.1 (C); 132.7 (C); 129.4 (CH); 128.6 (CH); 128.0 (CH); 127.5 
(CH); 114.8 (CH); 70.1 (CH2); 53.4 (CH2); 47.9 (CH2); 29.9 (CH2). IR υ 3289 (R-NH-R1); 3032 (Ar-
H); 1106 (C-N-C); 1239 and 1026 (Ar-O-C) cm-1. ESI-HRMS: calculated mass for C31H35N2O2 
(M+H+) 467.2699; found 467.2678. 
4.6.14. Synthesis of N1,N4-bis(4-(benzyloxy)benzyl)butane-1,4-diamine (14). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 168 mg of white solid (isolated yield: 77 %). 1H NMR (CDCl3) δ7.42 
(m, 10H, aromatics 4’-benzyloxy); 7.22 (d, 4H, J= 8.7 Hz, C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
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5.05 (s, 4H, Ar-CH2-O); 3.71 (s, 4H, Ar-CH2-N); 2.62 (t, 4H, J= 6.6 Hz, N-CH2); 1.53 (m, 4H, C2-H 
and C4-H). 13C NMR (CDCl3) δ 157.8 (C); 137.1 (C); 132.9 (C); 129.3 (CH); 128.6 (CH); 127.9 (CH); 
127.5 (CH); 114.8 (CH); 70.1 (CH2); 53.4 (CH2); 49.2 (CH2); 27.9 (CH2). IR υ 3294 (R-NH-R1); 3035 
(Ar-H); 1167 (C-N-C); 1247 and 1015 (Ar-O-C); 814 (disubstituted aromatic) cm-1. ESI-HRMS: 
calculated mass for C32H37N2O2 (M+H+) 481.2855; found 481.2849. 
4.6.15. Synthesis of N1,N6-bis(4-(benzyloxy)benzyl)hexane-1,6-diamine (15). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 155 mg of white solid (isolated yield: 86 %). 1H NMR (CDCl3) δ7.38 
(m, 10H, aromatics 4’-benzyloxy); 7.23 (d, 4H, J= 8.7 Hz, C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
5.05 (s, 4H, Ar-CH2-O); 3.72 (s, 4H, Ar-CH2-N);2.61 ( t, 4H, J= 6.9 Hz, N-CH2); 1.51 (m, 4H, C2-H 
and C5-H); 1.32 (m, 4H, C3-H and C4-H). 13C NMR (CDCl3) δ 157.9 (C); 137.1 (C); 132.3 (C); 129.5 
(CH); 128.6 (CH); 127.9 (CH); 127.5 (CH); 114.8 (CH); 70.0 (CH2); 53.2 (CH2); 49.1 (CH2); 29.7 
(CH2); 27.2 (CH2). IR υ 3293 (R-NH-R1); 3048 (Ar-H); 1104 (C-N-C); 1251 and 1016 (Ar-O-C); 
815(disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C34H41N2O2 (M+H+) 509.3168; 
found 509.3146. 
4.6.16. Synthesis of N1,N8-bis(4-(benzyloxy)benzyl)octane-1,8-diamine (16). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 147 mg of white solid (isolated yield: 99 %). 1H NMR (CDCl3) δ7.42 
(m, 10H, aromatics 4’-benzyloxy); 7.23 (d, 4H, J= 8.7 Hz, C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
5.05 (s, 4H, Ar-CH2-O); 3.72 (s, 4H, Ar-CH2-N); 2.60 ( t, 4H, J= 7.2 Hz, N-CH2); 1.49 (m, 4H, C2-H 
and C7-H); 1.29 (m, 8H, CH2. C3-H to C6-H). 13C NMR (CDCl3) δ 157.8 (C); 137.1 (C); 133.0 (C); 
129.3 (CH), 128.6 (CH), 127.9 (CH), 127.5 (CH); 114.8 (CH); 70.0 (CH2); 53.5 (CH2); 49.4 (CH2); 
30.1 (CH2); 29.5 (CH2); 27.3 (CH2). IR υ 3246 (R-NH-R1); 3035 (Ar-H); 1104 (C-N-C); 1249 and 
1015 (Ar-O-C); 813 (disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C36H45N2O2 
(M+H+) 537.3481; found 537.3477. 
4.6.17. Synthesis of N1,N10-bis(4-(benzyloxy)benzyl)decane-1,10-diamine (17). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 79 mg of white solid (isolated yield: 60 %). 1H NMR (CDCl3) δ7.42 
(m, 10H, aromatics 4’-benzyloxy); 7.24 (d, 4H, J= 8.7 Hz,C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
5.05 (s, 4H, Ar-CH2-O); 3.72 (s, 4H, Ar-CH2-N);2.61 ( t, 4H, J= 6.9 Hz, N-CH2); 1.49 (m, 4H, C2-H 
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and C9-H); 1.27 (m, 12H, C3-H to C8-H) .13C NMR (CDCl3) δ 157.9 (C); 137.1 (C); 132.7 (C); 129.4 
(CH), 128.6 (CH), 128.0 (CH), 127.5 (CH); 114.8 (CH); 70.0 (CH2); 53.4 (CH2); 49.4 (CH2); 30.0 
(CH2); 29.5 (CH2); 27.6 (CH2). IR υ 3311 (R-NH-R1); 3049 (Ar-H); 1105 (C-N-C); 1250 and 1016 
(Ar-O-C); 814(disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C38H49N2O2 (M+H+) 
565.3794; found 565.3802. 
4.6.18. Synthesis of N1,N12-bis(4-(benzyloxy)benzyl)dodecane-1,12-diamine (18). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 143 mg of white solid (isolated yield: 99 %). 1H NMR (CDCl3) δ7.42 
(m, 10H, aromatics 4’-benzyloxy); 7.24 (d, 4H, J= 8.7 Hz, C2’-H); 6.93 (d, 4H, J= 8.7 Hz, C3’-H); 
5.05 (s, 4H, Ar-CH2-O); 3.72 (s, 4H, Ar-CH2-N); 2.61 ( t, 4H, J= 6.9 Hz, N-CH2); 1.49 (m, 4H, C2-H 
and C11-H ); 1.27 (m, 16H, C3-H to C10-H) . 13C NMR (CDCl3) δ 157.9 (C); 137.1 (C); 132.7 (C); 
129.4 (CH); 128.6 (CH); 128.0 (CH); 127.5 (CH); 114.8 (CH); 70.0 (CH2); 53.4 (CH2); 49.4 (CH2); 
30.0 (CH2); 29.5 (CH2); 27.6 (CH2). IR υ 3311 (R-NH-R1); 3049 (Ar-H); 1105 (C-N-C); 1250 and 
1016 (Ar-O-C); 814 (disubstituted aromatic) cm-1. ESI-HRMS: calculated mass for C38H49N2O2 
(M+H+) 565.3794; found 565.3802. 
4.6.19. Synthesis of 5,5'-((propane-1,3-diylbis(azanediyl)) bis(methylene))bis(2-
methoxyphenol) (19). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 180 mg of white solid (isolated yield: 96 %). 1H NMR (CDCl3) δ 
6.79 (m, 6H, aromatics); 3.87(s, 6H, O-CH3); 3.69 (s, 4H, Ar- CH2); 2.73 (t, 4H, J=6.6 Hz, N-CH2); 
1.74 (m, 2H, C2-H). 13C NMR (CDCl3) δ 146.8 (C); 146.7 (C); 134.1 (C); 118.9 (CH); 115.9 (CH); 
112.4 (CH); 56.1 (CH3); 53.1 (CH2); 47.5 (CH2); 30.0 (CH2). IR (KBr) υ 3449 (R-NH-R1); 3029 (Ar-
H); 2464 (Ar-O-H); 1280 and 1028 (Ar-O-C); 1132 (C-N-C) cm-1. ESI-HRMS: calculated mass for 
C19H27N2O4 (M+H+) 347.1971; found 347.1969. 
4.6.20. Synthesis of 5,5'-((butane-1,4-diylbis(azanediyl)) bis(methylene))bis(2-methoxyphenol) 
(20). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 131 mg of white solid (isolated yield: 80 %). 1H NMR (CDCl3) δ 
6.77 (m, 6H, aromatics); 3.87(s, 6H, O-CH3); 3.69 (s, 4H, Ar- CH2); 2.62 (t, 4H, J= 6.6 Hz, N-CH2); 
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1.56 (m, 4H, C2-H and C3-H). 13C NMR (CDCl3) δ 146.7 (C); 146.7 (C); 134.1 (C); 118.9 (CH); 
115.8 (CH); 112.4 (CH); 56.1 (CH3); 53.0 (CH2); 49.0 (CH2); 27.8 (CH2). IR (KBr) υ 3441(R-NH-R1); 
3040 (Ar-H); 2319 (Ar-O-H); 1255 and 1026 (Ar-O-C); 1138(C-N-C); 866 cm-1. ESI-HRMS: 
calculated mass for C20H29N2O4 (M+H+) 361.2127; found 361.2121. 
4.6.21. Synthesis of 5,5'-((hexane-1,6-diylbis(azanediyl)) bis(methylene))bis(2-methoxyphenol) 
(21). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 110 mg of white solid (isolated yield: 82 %). 1H NMR (CDCl3) δ 
6.80 (m, 6H, aromatics); 3.86 (s, 6H, O-CH3); 3.68 (s, 4H, Ar-CH2); 2.59 (t, 4H, J= 7.2 Hz, N-CH2); 
1.47 (m, 4H, C2-H and C5-H); 1.30(m, 4H, C3-H and C4-H). 13C NMR (CDCl3) δ 146.7 (C); 146.7 
(C); 134.1 (C); 118.9 (CH); 115.8 (CH); 112.4 (CH); 56.1 (CH3); 53.1 (CH2); 49.0 (CH2); 29.9 (CH2); 
27.4 (CH2). IR (KBr) υ 3465(R-NH-R1); 3031 (Ar-H); 2441 (Ar-O-H); 1286 and 1035 (Ar-O-C); 1131 
(C-N-C) cm-1. ESI-HRMS: calculated mass for C22H33N2O4 (M+H+) 389.2440; found 389.2442. 
4.6.22. Synthesis of 5,5'-((octane-1,8-diylbis(azanediyl)) bis(methylene))bis(2-methoxyphenol) 
(22). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 135 mg of white solid (isolated yield: 72 %). 1H NMR (CDCl3) δ 
6.80 (m, 6H, aromatics); 3.86 (s, 6H, O-CH3); 3.69 (s, 4H, Ar-CH2); 2.58 (t, 4H, J= 7.2 Hz, N-CH2); 
1.47 (m, 4H, C2-H and C7-H); 1.25 (m, 8H, C3-H to C6-H). 13C NMR (CDCl3) δ 146.8 (C); 146.7 
(C); 134.0 (C); 119.0 (CH); 115.9 (CH); 112.4 (CH); 56.1 (CH3); 53.1 (CH2); 49.0 (CH2); 29.9 (CH2); 
29.5 (CH2); 27.3 (CH2). IR (KBr) υ 3447(R-NH-R1); 2991 (Ar-H); 2445 (Ar-O-H); 1282 and 1033 
(Ar-O-C); 1131(C-N-C); 855 (trisubstituted aromatic) cm-1. ESI-HRMS: calculated mass for 
C24H37N2O4 (M+H+) 417.2753; found 417.2740. 
4.6.23. Synthesis of 5,5'-((decane-1,10-diylbis(azanediyl)) bis(methylene)) bis(2-
methoxyphenol) (23). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 74 mg of white solid (isolated yield: 72 %). 1H NMR (CDCl3) δ 6.82 
(m, 6H, aromatics); 3.86 (s, 6H, O-CH3); 3.70 (s, 4H, Ar- CH2); 2.60 (t, 4H, J= 7.2 Hz, N-CH2); 1.48 
(m, 4H, C2-H and C9-H); 1.25 (m, 12H, CH2 C3- H to C8-H). 13C NMR (CDCl3) δ 146.7 (C); 146.7 
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(C); 134.1 (C); 118.9 (CH); 115.8 (CH); 112.4 (CH); 56.1 (CH3); 53.1 (CH2); 49.0 (CH2); 29.9 (CH2); 
29.5 (CH2); 27.6 (CH2). IR (KBr) υ 3418 (R-NH-R1); 3033 (Ar-H); 2444 (Ar-O-H); 1282 and 1033 
(Ar-O-C); 1131(C-N-C); 873 (trisubstituted aromatic) cm-1. ESI-HRMS: calculated mass for 
C24H41N2O4 (M+H+) 445.3066; found 445.3050. 
4.6.24. Synthesis of 5,5'-((dodecane-1,12-diylbis(azanediyl)) bis(methylene))bis(2-
methoxyphenol) (24). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 86 mg of white solid (isolated yield: 46 %). 1H NMR (CDCl3) δ 6.82 
(m, 6H, aromatics); 3.86 (s, 6H, O-CH3); 3.70 (s, 4H, Ar- CH2); 2.60 (t, 4H, J= 7.2 Hz, N-CH2); 1.48 
(m, 4H, C2-H and C11-H); 1.25 (m, 16H, CH2 C3- H to C12-H). 13C NMR (CDCl3) δ 146.7 (C); 146.7 
(C); 134.1 (C); 118.9 (CH); 115.8 (CH); 112.4 (CH); 56.1 (CH3); 53.1 (CH2); 49.0 (CH2); 29.9 (CH2); 
29.5 (CH2); 27.6 (CH2). IR (KBr) υ 3418(R-NH-R1); 3033 (Ar-H); 2444 (Ar-O-H); 1282 and 1033 
(Ar-O-C); 1131(C-N-C); 873 (trisubstituted aromatic) cm-1.  
4.6.25. Synthesis of N1,N3-bis(4-(benzyloxy)-3-methoxybenzyl)propane-1,3-diamine (25). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 133 mg of white solid (isolated yield: 50 %). 1H NMR (CDCl3) δ7.37 
(m, 10H, aromatics 4’-benzyloxy); 6.82 (m, 6H, aromatics); 5.13 (s, 4H, Ar-CH2-O); 3.87 (s, 6H, O-
CH3); 3.70 (s, 4H, Ar-CH2-N); 2.69 (t,4H, J= 6.6 Hz, N-CH2-); 1.72 (m, 2H, C2-H). 13C NMR 
(CDCl3) δ 149.7 (C); 147.2 (C); 137.3 (C); 133.8 (C); 128.5 (CH); 127.8 (CH); 127.3 (CH); 120.2 
(CH); 114.1 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.9 (CH2); 48.0 (CH2); 30.2 (CH2). IR υ 3302 
(R-NH-R1); 3063 (Ar-H); 1264 and 1026 (Ar-O-C); 1139 (C-N-C) cm-1. ESI-HRMS: calculated mass 
for C33H39N2O4 (M+H+) 527.2910; found 527.2886. 
4.6.26. Synthesis of N1,N4-bis(4-(benzyloxy)-3-methoxybenzyl)butane-1,4-diamine (26). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 205 mg of white solid (isolated yield: 84 %). 1H NMR (CDCl3) δ7.39 
(m, 10H, aromatics 4’-benzyloxy); 6.82 (m, 6H, aromatics); 5.13 (s, 4H, Ar-CH2-O); 3.89 (s, 6H, O-
CH3); 3.70 (s, 4H, Ar-CH2-N); 2.64 (t,4H, J= 6.6 Hz, N-CH2); 1.56 (m, 4H, C2-H and C3-H). 13C 
NMR (CDCl3) δ 149.7 (C); 147.2 (C); 137.3 (C); 133.2 (C); 128.5 (CH), 127.8 (CH),127.3 (CH); 
120.3 (CH); 114.0 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.6 (CH2); 49.1 (CH2); 27.7 (CH2). IR 
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υ 3299 (R-NH-R1); 3066 (Ar-H); 1261 and 1032 (Ar-O-C); 1131 (C-N-C) cm-1
. 
ESI-HRMS: 
calculated mass for C34H41N2O2 (M+H+) 541.3066; found 541.3045. 
4.6.27. Synthesis of N1,N6-bis(4-(benzyloxy)-3-methoxybenzyl)hexane-1,6-diamine (27). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 159 mg of white solid (isolated yield: 81 %). 1H NMR (CDCl3) δ7.40 
(m, 10H, aromatics 4’-benzyloxy); 6.84 (m, 6H, aromatics); 5.13 (s, 4H, Ar-CH2-O); 3.89 (s, 6H, O-
CH3); 3.71 (s, 4H, Ar-CH2-N); 2.61 (t,4H, J= 7.2 Hz, N-CH2); 1.51 (m, 4H, C2-H and C5-H); 1.33 (m, 
4H, C3-H and C4-H). 13C NMR (CDCl3) δ 149.7 (C); 147.6 (C); 137.3 (C); 133.4 (C); 128.5 (CH); 
127.8 (CH); 127.3 (CH); 120.3 (CH); 114.0 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.7 (CH2); 
49.3 (CH2); 29.8 (CH2); 27.3 (CH2). IR υ 3409 (R-NH-R1); 1264 and 1004 (Ar-O-C); 1145 (C-N-C) 
cm-1. ESI-HRMS: calculated mass for C36H45N2O4 (M+H+) 569.3379; found 569.3380. 
4.6.28. Synthesis of N1,N8-bis(4-(benzyloxy)-3-methoxybenzyl)octane-1,8-diamine (28). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 155 mg of white solid (isolated yield: 88 %). 1H NMR (CDCl3) δ7.39 
(m, 10H, aromatics 4’-benzyloxy); 6.84 (m, 6H, aromatics); 5.14 (s, 4H, Ar-CH2-O); 3.89 (s, 6H, O-
CH3); 3.71 (s, 4H, Ar-CH2-N); 2.61 (t, 4H, J= 7.2 Hz, N-CH2); 1.46 (m, 4H, C2-H and C7-H); 1.29 
(m, 8H, C3-H to C6-H). 13C NMR (CDCl3) δ 149.7 (C); 147.2 (C); 137.3 (C); 133.2 (C); 128.5 (CH); 
127.8 (CH); 127.3 (CH); 120.3 (CH); 114.0 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.7 (CH2); 
49.3 (CH2); 29.8 (CH2); 29.4 (CH2); 27.2 (CH2). IR υ 3410 (R-NH-R1); 3006 (Ar-H); 1259 and 1029 
(Ar-O-C); 1162 (C-N-C) cm-1. ESI-HRMS: calculated mass for C38H49N2O4 (M+H+) 597.3692; found 
597.3717. 
4.6.29. Synthesis of N1,N10-bis(4-(benzyloxy)-3-methoxybenzyl)decane-1,10-diamine (29). 
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 130 mg of white solid (isolated yield: 89 %). 1H NMR (CDCl3) δ7.40 
(m, 10H, aromatics 4’-benzyloxy); 6.81 (m, 6H, aromatics); 5.14 (s, 4H, Ar-CH2-O); 3.89 (s, 6H, O-
CH3); 3.71 (s, 4H, r-CH2-N); 2.61 (t,4H, N-CH2); 1.51 (m, 4H, C2-H and C9-H); 1.27 (m, 12H, C3-
H to C8-H). 13C NMR (CDCl3) δ 149.7 (C); 147.2 (C); 137.3 (C); 133.6(C); 128.5 (CH); 127.8 (CH); 
127.3 (CH); 120.3 (CH); 114.0 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.8 (CH2); 49.4 (CH2); 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT  
 
30.0 (CH2); 29.5 (CH2); 27.4 (CH2). IR υ 3422 (R-NH-R1); 1263 and 1029 (Ar-O-C); 1140 (C-N-C) 
cm-1. ESI-HRMS: calculated mass for C40H53N2O4 (M+H+) 625.4005; found 625.4030. 
4.6.30. Synthesis of N1,N12-bis(4-(benzyloxy)-3-methoxybenzyl) dodecane-1,12-diamine (30).  
Following the general reaction conditions for the disubstituted diamines synthesis, the reaction was 
worked up and purified to afford 135 mg of white solid (isolated yield: 90 %). 1H NMR (CDCl3) δ7.40 
(m, 10H, aromatics 4’-benzyloxy); 6.81 (m, 6H, aromatics); 5.14 (s, 4H, Ar-CH2-O); 3.89 (s, 6H, O-
CH3); 3.71 (s, 4H, Ar-CH2-N); 2.61 (t, 4H, N-CH2); 1.51 (m, 4H, C2-H and C11-H); 1.27 (m, 16H, 
C3-H to C10-H). 13C NMR (CDCl3) δ 149.7 (C); 147.2 (C); 137.3 (C); 133.6 (C); 128.5 (CH); 127.8 
(CH); 127.3 (CH); 120.3 (CH); 114.0 (CH); 112.0 (CH); 71.1 (CH2); 56.0 (CH3); 53.8 (CH2); 49.4 
(CH2); 30.0 (CH2); 29.5 (CH2); 27.4 (CH2). IR υ 3422 (R-NH-R1); 1263 and 1029 (Ar-O-C); 1140 (C-
N-C) cm-1. ESI-HRMS: calculated mass for C42H57N2O4 (M+H+) 653.4313; found 653.4313. 
4.7. General procedure for N,N,N’,N’-diamines tetrasubstituted synthesis  
To a solution of aldehyde (4.5 eq.) and diamine (1 eq) in anhydrous DCM, NaBH(AcO)3 (7.2 eq.) 
and acetic acid (6.4 eq.) were added at room temperature. The reaction was stirred under inert 
atmosphere for 24 hours and then was quenched with a 10% NaHCO3. Solution. Phases were separated 
and the aqueous phase extracted with DCM (3 x 20 mL). Combined organic extracts were dried with 
sodium sulphate and evaporated. Products were purified by flash chromatography. 
4.7.1 Synthesis of N1,N1,N3,N3-tetrabenzyl-propane-1,3-diamine (31). 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 29 mg of white solid (isolated yield: 17 %). 1H NMR (CDCl3) δ 
7.28 (m, 20H, aromatics); 3.51 (s, 8H, Ar-CH2); 2.42 (t, 4H, J= 6.9 Hz, N-CH2); 1.73 (m, 2H, C2-H). 
13C NMR (CDCl3) δ 139.7 (C); 128.9 (CH); 128.2 (CH); 126.8 (CH); 58.4 (CH2); 51.6 (CH2); 24.5 
(CH2). IR υ 3026 (Ar-H); 1127 (C-N); 697 (monosubstituted aromatic) cm-1. ESI-HRMS: calculated 
mass for C31H35N2 (M+H+) 435.2800; found 435.2781. 
4.7.2 Synthesis of N1,N1,N4,N4-tetrabenzylbutane-1,4-diamine (32) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 42 mg of white solid (isolated yield: 26 %). 1H NMR (CDCl3) δ 
7.31 (m, 20H, aromatics); 3.50 (s, 8H, Ar-CH2); 2.35 (t, 4H, J= 4.8 Hz, N-CH2); 1.49 (m, 4H, C2-H 
and C3-H). 13C NMR (CDCl3) δ 140.0 (C); 128.8 (CH); 128.2 (CH); 126.07 (CH); 58.3 (CH2); 53.4 
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(CH2); 24.8 (CH2). IR υ 3028 (Ar-H); 1123 (C-N); 693 (monosubstituted aromatic) cm-1. ESI-HRMS: 
mass calculated for C32H37N2 (M+H+) 449.2957; found 449.2964. 
4.7.3 Synthesis of N1,N1,N6,N6-tetrabenzylhexane-1,6-diamine (33) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 27 mg of white solid (isolated yield: 17 %). 1H NMR (CDCl3) δ 
7.31 (m, 20H, aromatics); 3.53 (s, 8H, Ar-CH2); 2.36 (t, 4H, J=6.9 Hz, N-CH2); 1.45 (m, 4H, C2-H 
and C5-H); 1.17 (m, 4H, C3-H and C4-H). 13C NMR (CDCl3) δ 140.1 (C); 128.8 (CH); 128.1 (CH); 
126.7 (CH); 58.3 (CH2); 53.4 (CH2); 27.1 (CH2); 27.0 (CH2). IR υ 3026 (Ar-H); 1120 (C-N); 698 
(monosubstituted aromatic) cm-1. ESI-HRMS: mass calculated for C34H41N2 (M+H+) 477.3270; found 
477.3273. 
4.7.4 Synthesis of N1,N1,N8,N8-tetrabenzyloctane-1,8-diamine (34) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 28 mg of white solid (isolated yield: 27 %). 1H NMR (CDCl3) δ 
7.32 (m, 20H, aromatics); 3.54 (s, 8H, Ar-CH2); 2.39 (t, 4H, J= 6.9, N-CH2); 1.47 (m, 4H, C2-H and 
C7-H); 1.22 (m, 8H, C3-H to C6-H ). 13C NMR (CDCl3) δ140.1 (C); 128.8 (CH); 128.1 (CH); 126.7 
(CH); 58.3 (CH2); 53.4 (CH2); 29.5 (CH2); 27.3 (CH2); 27,0 (CH2). IR υ 3026 (Ar-H); 1126 (C-N); 
697 (monosubstituted aromatic) cm-1.  
4.7.5 Synthesis of N1,N1,N10,N10-tetrabenzyldecane-1,10-diamine (35) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 26 mg of white solid (isolated yield: 28 %). 1H NMR (CDCl3) δ 
7.32 (m, 20H, aromatics); 3.54 (s, 8H, Ar-CH2); 2.39 (t, 4H, J=7.2 Hz, N-CH2); 1.48 (m, 4H, C2-H 
and C9-H); 1.17 (s, 12H, C3-H to C8-H). 13C NMR (CDCl3) δ 140.1 (C); 128.8 (CH); 128.1 (CH); 
126.7 (CH); 58.3 (CH2); 53.4 (CH2); 29.6 (CH2); 29.5 (CH2); 27.3 (CH2); 27.0 (CH2). ESI-HRMS: 
calculated mass for C38H49N2 (M+H+) 533.3892, found 533.3896. 
4.7.6 Synthesis of N1,N1,N3,N3-tetrakis(4-methoxybezcyl)propane-1,3-diamine (36) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 194 mg of yellowish oil (isolated yield: 30%). 1H NMR (CDCl3) 
δ 7.16 (d, 8H, J=8.7 Hz, aromatics); 6.81(d, 8H, J = 8.7 Hz, aromatics); 3.79 (s, 12H, O-CH3); 3.40 (s, 
8H, Ar-CH2); 2.36 (t, 4H, J= 6,9 Hz, N-CH2); 1.67 (m, 2H, C2). 13C NMR (CDCl3) δ 158.5 (C); 132.0 
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(C); 130.0 (CH); 113.5 (CH); 57.5 (CH2); 55.2 (CH3); 51.3 (CH2); 24.5 (CH2). IR υ 2997 (Ar-H); 1247 
and 1034 (Ar-O-C); 1179 (C-N) cm-1. ESI-HRMS: calculated mass for C35H43N2O4 (M+H+) 555.3223; 
found 555.3235. 
4.7.7 Synthesis of N1,N1,N4,N4-tetrakis(4-methoxybenzyl)butane-1,4-diamine (37) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 45 mg of white solid (isolated yield: 25%). 1H NMR (CDCl3) δ 
7.22 (d, 8H, J= 8.7 Hz, aromatics); 6.83(d, 8H, J = 8.7 Hz, aromatics); 3.79 (s, 12H, -O-CH3); 3.42 (s, 
8H, Ar-CH2); 2.31 (t, 4H, N-CH2); 1.44 (m, 4H, C2-H and C3-H). 13C NMR (CDCl3) δ158.5 (C); 
132.1 (C); 129.9 (CH); 113.5 (CH); 57.4 (CH2); 55.3 (CH3); 51.3 (CH2); 24.8 (CH2). IR υ 2998 (Ar-
H); 1247 and 1037 (Ar-O-C); 1178 (C-N) cm-1. ESI-HRMS: mass calculated for C36H45N2O4 (M+H+) 
569.3379; found 569.3385. 
4.7.8 Synthesis of N1,N1,N6,N6-tetrakis(4-methoxybenzyl)hexane-1,6-diamine (38) 
Following the general reaction conditions for the tetrasubstituted diamines synthesis, the reaction 
was worked up and purified to afford 21 mg of white solid (isolated yield: 10%). 1H NMR (CDCl3) δ 
7.24 (d, 8H, J=8.7 Hz, aromatics); 6.83(d, 8H, J= 8.7 Hz, aromatics); 3.79 (s, 12H, O-CH3); 3.45 (s, 
8H, Ar-CH2); 2.33 (t, 4H, J= 7.2 Hz, N-CH2); 1.46 (m, 4H, C2-H and C5-H); 1.16 (m, 4H, C3-H and 
C4-H). 13C NMR (CDCl3) δ 158.4 (C); 132.0 (C); 129.8 (CH); 113.5 (CH); 57.3 (CH2); 55.2 (CH3); 
51.1 (CH2); 27.2 (CH2); 27.0 (CH2). IR υ 3032 (Ar-H); 1247 and 1036 (Ar-O-C); 1170 (C-N) cm-1. 
ESI-HRMS: mass calculated for C38H49N2O4 (M+H+) 597.3692; found 597.3718. 
4.7.9 Synthesis of N1,N1,N8,N8-tetrakis(4-methoxybenzyl)octane-1,8-diamine (39) 
Following the general reaction conditions for the tetrasubstitutes diamines synthesis, the reaction 
was worked up and purified to afford 20 mg of white solid (isolated yield: 16%). 1H NMR (CDCl3) δ 
7.25 (d, 8H, J= 8.7 Hz, aromatics); 6.84 (d, 8H, J= 8.7 Hz, aromatics); 3.79 (s, 12H, O-CH3); 3.46 (s, 
8H, Ar-CH2); 2.37 (t, 4H, J= 7.2 Hz, N-CH2); 1.46 (m, 4H, C2-H and C7-H); 1.16 (s, 8H, C3-H to C6-
H). 13C NMR (CDCl3) δ 158.4 (C); 132.1 (C); 129.9 (CH); 113.5 (CH); 57.4 (CH2); 55.2 (CH3); 53.1 
(CH2); 29.6 (CH2); 27.3 (CH2); 27.3 (CH2). ESI-HRMS: mass calculated for C40H53N2O4 (M+H+) 
625.4005; found 625.4036. 
4.7.10 Synthesis of N1,N1,N10,N10-tetrakis(4-methoxybenzyl)decane-1,10 diamina (40) 
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Following the general reaction conditions for the tetrasubstitutes diamines synthesis, the reaction 
was worked up and purified to afford 21 mg of white solid (isolated yield: 28%). 1H NMR (CDCl3) 
δ7.25 (d, 8H, J= 8.7 Hz, aromatics); 6.84 (d, 8H, J = 8.7 Hz, aromatics); 3.79 (s, 12H, O-CH3); 3.46 (s, 
8H, Ar-CH2); 2.36 (t, 4H, J= 7.5 Hz, N-CH2); 1.47 (m, 4H, C2-H and C9-H); 1.18 (s, 12H, CH2, C3-H 
to C8-H). 13C NMR (CDCl3) δ 158.4 (C); 132.0 (C); 129.9 (CH); 113.5 (CH); 57.4 (CH2); 55.2 (CH3); 
53.0 (CH2); 29.8 (CH2); 29.5 (CH2); 27.3 (CH2); 26.9 (CH2). ESI-HRMS: mass calculated for 
C42H57N2O4 (M+H+) 653.4318; found 653.4340. 
4.8 Computational methods  
The geometries of the products were optimized using B3LYP functional54-56 together with 6-
311++G(d,p) basis set. The B3LYP has shown to be appropriate to obtain reliable geometries and for 
describing electronic density surfaces. All calculations were performed with the Gaussian 09 
package.57  
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Figure 1. Structure of MDL-27695 and our strategy.  
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CHO
R
+
H2N NH2
n 1. DCM:MeOH (3:1) 
reflux HN
H
N
n
RR
n= 3, 4, 6, 8, 10, 12
R= H; 4-OMe; 4-OBn; 
3-OH,4-OMe and 
3-OMe,4-OBn
2. NaBH4
DCM:MeOH (1:1) Compounds 1-30
  
Scheme 1. Synthesis of N,N’-derivatives. 
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Table 1. Anti-apicomplexan activity, cytotoxicity and cluster family of N, N’-substituted diamines. 
 
Compound n R Yield*(%) 
P. falciparum 
D6 
IC50 (µM) 
SIa 
P. falciparum 
W2 
IC50 (µM) 
SIa 
T. gondii 
Growth 
inhibition at 
1 µMb 
Cytotoxicity
Vero cells 
IC50 (µM) c 
Cluster 
1 3 H 79 2.35 >7.9 2.63 >7.1 + NC A 
2 4 H 73 2.98 >5.9 2.49 >7.1 + NC A 
3 6 H 46 2.09 >7.7 2.09 >7.7 + NC B 
4 8 H 94 0.37 >39.7 0.37 >39.7 + NC B 
5 10 H 89 0.48 >28.0 0.28 >47.6 +++ NC B 
6 12 H 79 0.97 >12.9 1.02 >12.2 + NC B 
7 3 4-OMe 78 3.18 >4.8 5.41 >2.8 ++ NC C 
8 4 4-OMe 77 4.57 >3.2 6.69 >2.2 + NC D 
9 6 4-OMe 30 3.08 2.4 3.36 2.5 + 8.32 E 
10 8 4-OMe 59 1.48 >8.4 1.69 >7.3 + 
+ 
NC F 
11 10 4-OMe 66 0.60 >19.0 0.67 >17.0 ++ 
 
NC F 
12 12 4-OMe 99 1.58 >6.8 1.86 >5.8 +++ NC F 
13 3 4-OBn 67 1.22 4.9 1.43 4.2 +++ 6.00 G 
14 4 4-OBn 77 2.08 2.8 3.12 1.9 ++ 5.83 H 
15 6 4-OBn 86 0.39 >24.0 0.29 >32.2 + NC I 
16 8 4-OBn 99 3.72 >2.4 4.09 >2.2 + NC J 
17 10 4-OBn 60 2.47 >3.4 3.50 >2.4 +++ NC J 
18 12 4-OBn 99 8.00 >1.2 8.00 >1.2 ND NC J 
19 3 3-OH, 4-OMe 
 
96 >8.00 - >8.00 - ND NC C 
20 4 3-OH, 4-OMe 
3-OH, 4-OMe 
80 >8.00 - >8.00 - +++ NC D 
21 6 3- , 4- e 
 
82 >8.00 - >8.00 - ++ NC E 
22 8 3-OH, 4-OMe 
 
78 4.80 >2.38 5.52 >2.1 + NC F 
23 10 3-OH, 4-OMe 
 
72 1.97 >5.41 1.88 >5.7 + NC F 
24 12 3-OH, 4-OMe 
 
46 1.97 >5.10 2.88 >3.5 + NC F 
25 3 3-OMe, 4-OBn 
3-OMe, 4-OBn 
50 0.42 15.9 0.47 14.1 ++++ 6.65 G 
26 4 - , -  
 
84 0.33 >27.4 0.49 >18.4 ++ NC H 
27 6 3-OMe, 4-OBn 
 
81 0.26 >31.7 0.44 >19.0 + NC I 
28 8 3-OMe, 4-OBn 
 
88 0.31 14.6 0.43 10.5 - 4.52 J 
29 10 3-OMe, 4-OBn 
3-OMe, 4-OBn 
89 1.12 >6.8 1.05 >7.2 + NC J 
30 12 3-OMe, 4-OBn 99 1.28 >5.67 1.37 >5.3 + NC J 
31 3 H tetrasubstituted 17 >8.00 - >8.00 - ND NC K 
32 4 H tetrasubstituted 26 >8.00 - >8.00 - ND NC K 
33 6 H tetrasubstituted 17 >8.00 - >8.00 - ND NC L 
34 8 H tetrasubstituted 27 >8.00 - >8.00 - ND NC L 
35 10 H tetrasubstituted 28 >8.00 - >8.00 - ND NC L 
36 3 4-OMe Tetrasubt. 30 >8.00 - >8.00 - ND NC K 
37 4 4-OMe Tetrasubt. 25 >8.00 - >8.00 - ND NC K 
38 6 4-OMe Tetrasubt. 10 >8.00 - >8.00 - ND NC L 
39 8 4-OMe Tetrasubt. 16 >8.00 - >8.00 - ND NC L 
40 10 4-OMe Tetrasubt. 28 >8.00 - >8.00 - ND NC L 
CQ    0.083  0.422     
Art    0.094  0.094     
Pyr        -   
NC= not cytotoxic at the maximum concentration tested (4.46 ug/mL) CQ= Chloroquine Art= Arteminsin 
Pyr=pyremethamine.  
 
a-SI (Selectivity Index: IC50 Vero Cells / IC50 Parasites) 
b  Scale: ++++ total growth inhibition of parasite with fibroblast integrity, +++ Some tachizoite growth but approximately 
at 75 % of control with fibroblast integrity, ++ correspond at 50% of parasite  growth, + at 25% and - no growth inhibition.  
c-Tested a t a maximum concentration of 8 µM 
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Figure 2. Antimalarial activity (D6 Clone) by substituent. The average value of each subset is shown. 
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Figure 3. Cluster and dendrogram analysis of N,N’-di substituted diamine library. 
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Figure 4. Distribution of compounds of synthetic library vs. physicochemical properties.  
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Figure 5. Parasitic activities (P. falciparum and T. gondii) vs. logP. 
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Table 2. Physicochemical properties of N, N’-substituted diamines. 
Compound n R MW LogP LogD LogBB TPSA Volume 
1 3 H 254.377 2.538 0,46 0.373 24.06 264.27 
2 4 H 268.404 2.994 
-0,88 0.436 24.06 281.07 
3 6 H 296.458 3.906 
-0,01 0.584 24.06 314.67 
4 8 H 324.512 4.818 0,88 0.735 24.06 348.27 
5 10 H 352.566 5.730 1,77 0.851 24.06 381.88 
6 12 H 380.620 6.642 2,66 1.005 24.06 415.48 
7 3 4-OMe 314.429 2.807 0,26 0.119 42.52 315.36 
8 4 4-OMe 328.456 3.261 
-1,09 0.193 42.52 332.16 
9 6 4-OMe 356.510 4.095 
-0,16 0.670 42.52 365.76 
10 8 4-OMe 384.564 4.930 0,73 0.747 42.52 399.37 
11 10 4-OMe 412.618 5.764 1,62 0.929 42.52 432.97 
12 12 4-OMe 440.672 6.599 2,51 1.082 42.52 466.57 
13 3 4-OBn 466.625 6.272 3,64 0.300 42.52 458.66 
14 4 4-OBn 480.652 6.726 2,35 0.370 42.52 475.46 
15 6 4-OBn 508.706 7.560 3,23 0.812 42.52 509.06 
16 8 4-OBn 536.760 8.395 4,12 0.944 42.52 542.66 
17 10 4-OBn 564.814 9.230 5,01 1.098 42.52 576.27 
18 12 4-OBn 592.868 10.064 5,89 1.252 42.52 609.87 
19 3 3-OH, 4-OMe 
 
346.427 2.028 0,23 -0.308 82.98 331.39 
20 4 3-OH, 4-OMe 
3-OH, 4-OMe 
360.454 2.482 
-0,83 -0.294 82.98 348.19 
21 6 3- , 4- e 
 
388.508 3.316 0,05 0.142 82.98 381.80 
22 8 3-OH, 4-OMe 
 
416.562 4.151 0,94 0.297 82.98 415.40 
23 10 3-OH, 4-OMe 
 
444.616 4.985 1,83 0.448 82.98 449.01 
24 12 3-OH, 4-OMe 
 
472.670 5.820 2,71 0.604 82.98 482.61 
25 3 3-OMe, 4-OBn 
3-OMe, 4-OBn 
526.680 6.030 3,48 0.116 60.98 509.75 
26 4 - , -  
 
540.704 6.473 2,26 0.130 60.98 526.55 
27 6 3-OMe, 4-OBn 
 
568.758 7.308 3,12 0.593 60.98 560.15 
28 8 3-OMe, 4-OBn 
 
596.812 8.142 4,02 0.776 60.98 593.76 
29 10 3-OMe, 4-OBn 
3-OMe, 4-OBn 
624.866 8.977 4,95 0.942 60.98 627.36 
30 12 3-OMe, 4-OBn 652.920 8.977 5,92 1.057 60.98 660.96 
31 3 H TetraSubst. 
3-OMe, 4-OBn 
434.63 6.24 4.84 NC 6.48 441.45 
32 4 H TetraSubst. 448.65 6.51 3.32 NC 6.48 458.25 
33 6 H TetraSubst. 476.71 7.52 4.20 NC 6.48 491.86 
34 8 H TetraSubst. 504.76 8.42 5.09 NC 6.48 525.46 
35 10 H TetraSubst. 532.82 8.93 5.97 NC 6.48 559.06 
36 3 4-OMe TetraS. 498.62 4.32 3.95 NC 87.39 473.52 
37 4 4-OMe TetraS. 512.65 4.59 2.61 NC 87.39 490.32 
38 6 4-OMe TetraS. 540.70 5.60 3.49 NC 87.39 523.93 
39 8 4-OMe TetraS. 568.76 6.61 4.38 NC 87.39 557.53 
40 12 4-OMe TetraS. 596.81 7.62 5.27 NC 87.39 591.13 
NC= not calculated 
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H2N NH2
CHOR
n
n = 1,2,4,6,8
R = H or OMe
NaBH(AcO)3, HAcO
DCM
r.t. 24 h. N Nn
R
R R
R
Compounds 31-40
 
Scheme 2. Synthesis of N,N,N’,N’-derivatives. 
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Figure 6. N-Methyl benzylamine portion of the N,N´-dibenzyldiamines prepared. A) Structure of 
the five benzylamines, B) Minimum energy conformation for each compound, C) Molecular electronic 
potential maps onto a van der Waals surface (isodensity 0.001 e/au3) for the N-Methyl benzylamines. 
The color-coded is shown at the left (in the range of 0.1408 au (deepest red) to +0.1152 au (deepest 
blue)).  
A 
B 
C 
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Figure 7. Structure-activity relationship of our library against apicomplexan and selected analogs. 
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Highlights 
• A series of N,N´-disubstituted aliphatic diamines and N,N,N´,N´-tetrasubstituted aliphatic 
diamines were designed and synthesized as potential new chemical entitites for malaria and 
toxoplasmosis drug development. 
• All compounds were tested in Toxoplasma gondii and in chloroquine-sensitive and resistant- 
strains of Plasmodium falciparum. 
• Most of the synthesized compounds showed potent activity in P. falciparum, and can be used 
as a starting point for the development of new antimalarial drugs. On the other hand, none of 
the tetrasubstituted analogues were active. 
• The collection did not show the same potency on T. gondii and was different when compared 
with the malaria parasite.  
• Theoretical studies were carried out to show the electronic differences between the synthesized 
compounds. A possible multitarget action mechanism have been proposed.  
